NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 908.1 DKK | -0.53% |
|
-0.21% | +30.07% |
| May. 16 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| May. 16 | Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark | MT |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.75% | ||
| 10.45% | 5 M€ | +14.70% | ||
| 5.40% | 17 M€ | +7.73% | - | |
| 4.67% | 88 M€ | +10.37% | - | |
| 3.95% | 4 M€ | -.--% | - | |
| 3.91% | 5 M€ | +10.09% | - | |
| 3.91% | 14 M€ | +5.66% | - | |
| 3.78% | 6 M€ | -.--% | ||
| 3.09% | 12 M€ | +15.09% | - | |
| 3.02% | 6 M€ | -.--% | - | |
| 2.87% | 29 M€ | +8.37% | - | |
| 2.53% | 3,859 M€ | +18.82% | - | |
| 2.53% | 469 M€ | -2.05% | ||
| 2.22% | 3 M€ | +9.95% | - | |
| 1.91% | 2 M€ | -.--% | - | |
| 1.91% | 2 M€ | +9.19% | - | |
| 1.67% | 10 M€ | -3.35% | - | |
| 1.60% | 10 M€ | +6.14% | - | |
| 1.31% | 253 M€ | +7.93% | ||
| 1.30% | 48 M€ | +10.40% | ||
| 1.21% | 17 M€ | +5.95% | ||
| 1.04% | 276 M€ | +11.40% | - | |
| 1.03% | 7 M€ | +6.24% | - | |
| 0.89% | 1,083 M€ | +4.45% | ||
| 0.79% | 284 M€ | -.--% | ||
| 0.76% | 786 M€ | -.--% | ||
| 0.76% | 23 M€ | -.--% | - | |
| 0.75% | 206 M€ | -.--% | ||
| 0.70% | 7 M€ | +0.11% | - | |
| 0.64% | 264 M€ | -.--% | - | |
| 0.64% | 187 M€ | +11.11% | - | |
| 0.64% | 477 M€ | +12.59% | ||
| 0.57% | 727 M€ | +9.25% |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.74% | 593B | |
| +32.36% | 694B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.42% | 239B | |
| +10.00% | 209B | |
| -3.11% | 209B | |
| +9.27% | 169B | |
| +0.45% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S
